Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib

Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults

(2016) Linh Nguyen et al.   ANTI-CANCER DRUGS

Population pharmacokinetic/pharmacodynamic modeling of tumor growth kinetics in medullary thyroid cancer patients receiving cabozantinib

(2016) Dale R. Miles et al.   ANTI-CANCER DRUGS

A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma

(2016) William Travis Foxx-Lupo et al.   Clinical Genitourinary Cancer

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

(2016) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

(2016) Toni K Choueiri et al.   LANCET ONCOLOGY

Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition

(2015) Linna Zhang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors

(2015) N. A. Cohen et al.   CANCER RESEARCH

Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models

(2015) M. Sameni et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis

(2015) Dale Miles et al.   CLINICAL PHARMACOKINETICS

Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects

(2015) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

(2015) Linh Nguyen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Toni K. Choueiri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

(2015) L Zhou et al.   ONCOGENE

A phase I study of cabozantinib (XL184) in patients with renal cell cancer

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET

(2014) Q. Xiang et al.   CLINICAL CANCER RESEARCH

Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model

(2014) Eun-Kee Song et al.   INTERNATIONAL JOURNAL OF CANCER

Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein

(2014) Qing-feng Xiang et al.   LIVER INTERNATIONAL

Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions

(2013) Jinlu Dai et al.   CLINICAL CANCER RESEARCH

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

(2013) Frauke Bentzien et al.   THYROID

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

MET signalling: principles and functions in development, organ regeneration and cancer

(2010) Livio Trusolino et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting the Met signaling pathway in renal cancer

(2009) Alessio Giubellino et al.   Expert Review of Anticancer Therapy

Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient

(2009) Brian I. Rini   JOURNAL OF CLINICAL ONCOLOGY

Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors

(2008) M. L. Nickerson et al.   CLINICAL CANCER RESEARCH

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY